Embla Medical (EMBLA) Q4 2025 earnings summary

Executive summary

• Achieved solid organic sales growth of 6% for FY 2025 and 7% in Q4, with reported growth at 9% and 14% respectively, driven by strong performance in prosthetics and neuroorthotics, and EMEA region momentum.

• Completed majority investment in Streifeneder ortho.production, expanding presence in key markets and enhancing product range.

• Opened first clinic in Ukraine and launched a partnership with the Icelandic government to support Ukrainian amputees.

• Rebranded Patient Care facilities to ForMotion in multiple regions and recognized among the world's top 500 companies for sustainable growth.

• Achieved strong topline, net profit growth, and cash flow generation in Q4 and FY 2025.

Financial highlights

• Q4 2025 sales reached USD 257 million, with 7% organic growth and 14% reported growth; FY 2025 sales totaled USD 929 million, up 6% organically and 9% reported.

• EBITDA margin was 20% for FY 2025 (on par with 2024) and 19% in Q4 (down from 21% in Q4 2024).

• Gross profit margin was 62% for both Q4 and the full year, slightly down from 63% in Q4 2024.

• Net profit grew 33% in Q4 and 21% for the full year compared to 2024, reaching USD 84 million for FY 2025.

• Free cash flow for FY 2025 was USD 100 million (11% of sales), up from USD 75 million (9% of sales) in 2024.

Outlook and guidance

• Issued 2026 guidance of 5%-8% organic sales growth and an EBITDA margin of 20%-22%.

• Growth expected to be driven by continued momentum in prosthetics and neuroorthotics, new product launches, and Medicare coverage expansion in the US.

• Patient Care segment expected to recover, with growth initiatives implemented in 2025.

• Bracing & Supports expected to return to market growth in 2026, with new product launches planned.

• CAPEX guidance for 2026 is 3%-4% of sales; effective tax rate expected at 23%-24%.